CDK9 and breast carcinoma: Eventually, researchers have discovered a direct relationship between ALK and cyclin-dependent kinase 9 (CDK9) in breast cancer, where ALK phosphorylates CDK9, leading to resistance against Poly(ADP-Ribose) Polymerase (PARP) inhibitors and encouraging homologous recombination repair.